Not Yet RecruitingPhase 4

Dinalbuphine Sebacate in Postoperative Pain Control After TKA

Thailand100 participantsStarted 2025-10

Plain-language summary

To evaluate the effectiveness of Dinalbuphine Sebacate for controlling subacute pain after total knee arthroplasty

Who can participate

Age range50 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Osteoarthritic knee patients underwent unilateral primary TKA * Age 50-90 years * ASA class I-III * Participants understand and consent to the protocol of the trial Exclusion Criteria: * Morbid obesity (BMI\>40) * Knee osteoarthritis from inflammatory knee arthritis, trauma, infection * Previous knee surgery * Cognitive disorder * Liver disease * Allergy to NSAIDs, opioids, sesame oil, and benzyl benzoate * CYP3A4 inhibitor and inducer drugs used

What they're measuring

Visual analog scale for pain (VAS 0-100)

Timeframe: Record every 12 hours after surgery until 2 weeks postoperatively, then once weekly until 12 weeks postopertively

Trial details

NCT IDNCT07140510

SponsorThammasat University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06

Contact for this trial

Supakit Kanitnate, M.D.

+66 899853635 naypeng@hotmail.com

View on ClinicalTrials.gov More Osteo Arthritis of the Knee trials